Feature|Videos|April 30, 2025

BioDuro is Redefining CRDMO Partnerships With End-to-End Innovation

Author(s)Bioduro

How BioDuro is expanding its global CRDMO footprint by improving integrated capabilities and delivering high-quality, end-to-end solutions for drug development and manufacturing

Armin Spura, PhD, CEO of BioDuro, talks about the company’s evolution into a fully integrated contract, research, and development manufacturing organization (CRDMO), offering seamless services across discovery to development and commercialization. Spura discusses recent expansions in commercial-scale API production, peptide scale-up, and high-potency capabilities at the company’s Bengbu, China location.

Watch this video and learn more about:

  • What differentiates BioDuro as a high-touch, high-quality CRDMO and how its integrated model streamlines drug development.
  • The company’s recent facility expansions in the U.S. and China in drug substance synthesis, peptide production, and more.
  • How BioDuro navigates geopolitical and regulatory landscapes while scaling global operations and client-specific solutions.

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.